Skip to main content

Vir Biotechnology Inc(VIR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Brii Biosciences Provides Latest Clinical Development and Corporate Updates

PR Newswire - Wed Jul 5, 2023

Company extends BRII-179 license to global rights and introduces preventive vaccine, PreHevbri®in Greater China and Asia Pacific markets

New data from BRII-835 + PEG-IFN-α study have demonstrated that robust anti-HBs antibody responses at the end of treatment are associated with sustained HBsAg loss 24 weeks post treatment

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe